692 completed Phase 1-3 PD trials (as of August 2, 2022)

To view publications of completed studies, you can search PubMed to find publication abstracts and authors, as well as links to full publications. Helpful keywords to use in a search are trial name, trial NCT# (i.e., ClinicalTrials.gov trial ID), principal investigator name, and sponsor name.  PubMed is a free resource developed by the National Center for Biotechnology Information (NCBI) at the U.S. NIH.    

​Note: Phase 1, 2 and 3 studies evaluate the safety and efficacy of a medication, device, or procedure for the treatment of a medical condition.  Phase 4 studies further evaluate a drug or device that has already been FDA-approved.  Studies with no phase specified can include evaluations of exercise, physical therapy, speech therapy, dietary supplements, devices & more.​

105 exercise-related trials as of 8/2/22

Parkinson's Disease interventional studies

2 cognitive therapy trials as of 8/2/22

11 dyskinesia trials as of 8/2/22

7 gene therapy trials as of 8/2/22

83 terminated Phase 1-3 PD trials (as of August 2, 2022)

provides breakdown of active Phase 1-3 PD drug trials by therapy type


... and click on country/state to view trial listings.

      ACTIVE TRIALS by THERAPY FOCUS (using keyword searches on ClinicalTrials.gov)


Note: 624 total active trials includes 386 recruiting, 97 not yet recruiting, 41 enrolling by invitation and 100 no longer recruiting.

An INTERVENTIONAL STUDY (or Clinical Trial) is a clinical study in which participants are assigned an intervention such as a medication, device, or procedure, so that researchers can evaluate its effects on biomedical or health-related outcomes.  Participants may receive diagnostic, therapeutic, or other types of interventions. (source: ClinicalTrials.gov - Glossary of Common Site Terms)

624 active PD interventional studies worldwide are registered on ClinicalTrials.gov, as of August 2, 2022. 

Active studies include trials that are recruiting, not yet recruiting, enrolling by invitation or no longer recruiting.

​​​Reporting requirements for clinical trials registered on ClinicalTrials.gov

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements
2008: ClinicalTrials.gov Releases Results Database

​2016: Final Rule for Clinical Trials Registration and Results Information Submission (Final Rule for FDAAA 801)

Reported results for completed Phase 1-3 PD trials with "primary completion date" after 1/1/17


91 DBS-related trials as of 8/2/22

16 telemedicine trials as of 8/2/22

14 alpha synuclein trials as of 8/2/22

Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.